Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2B and characterization of incomplete responders

American Journal of Gastroenterology

Volumn 91, Issue 10, 1996, Pages 2144-2149

  Hakozaki, Yukiya ^a   Shirahama, Tatsuoki ^b   Katou, Masashi ^b   Nakagawa, Katsuya ^b   Oba, Kenichi ^b   Yoshii, Osamu ^b   Matsumoto, Toshiharu ^b   Kuwabara, Noriyuki ^b   Mitamura, Keiji ^b  

^a Self Defense Forces Central Hospital   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029798634     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hakozaki Y, Shirahama T, Katou M, et al. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
2. Yano M. Criteria of IFN treatment for chronic hepatitis C. Nippon Rinsho (in Japanese). 1995;53(suppl):986-90.
3. Serfaty L, Giral P, Loria A, et al. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-7.
4. Budillon G, Cimino L, Vecchio Blanco C, et al. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon: A comparison of two protocols. Ital J Gastroenterol 1994;26:16-20.
5. Di Bisceglie AM, Hoofnagle JH. Therapy of chronic hepatitis C with alpha interferon: The answer? Or more questions? Hepatology 1991; 13:601-3.
6. Hino K, Okuda M, Konishi T, et al. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon alpha therapy. Dig Dis Sci 1995;40:14-20.
7. Kato N, Yokosuka O, Hosoda K, et al. Quantification of hepatitis C virus by competitive reverse transcription polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993;18: 16-20.
8. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-9.
9. Bianchi L, Gudat F. Chronic hepatitis: Pathology of the liver, 3rd edition. New York: Churchill Livingstone, 349-95.
10. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101:497-502.
11. Matsumoto A, Tanaka E, Suzuki T, et al. Viral and factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-80.
12. Metreau JM, Poupon R, Clamus Y, et al. Factors predictive of response to interferon therapy in NANB chronic active hepatitis. J Hepatol 1990;8:S45.
13. Reichard O, Glaumann H, Norkrans G, et al. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alpha 2b treatment course. Liver 1994;14:169-74.
14. Kanai K, Kato M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.